Verified Nov 2026
Other
·
Menlo Park, California
·
Since 2011
Sight Sciences is a publicly traded ophthalmic medical device company headquartered in Menlo Park, California, founded in 2011. It employs roughly 100 to 200 people and reports revenue in the range of $77.4 million. The company serves ophthalmologists, optometrists, hospitals, and medical centers in glaucoma and dry eye care. Its own products include the OMNI Surgical System for minimally invasive glaucoma surgery and the TearCare System for heat-based dry eye treatment. In August 2026, it received FDA 510(k) clearance for the OMNI Ultra Surgical System.
Sight Sciences at a glance
Revenue
77.4M
Employees
100-200
Founded
2011
Headquarters
Menlo Park, California
Ownership
Publicly traded (NASDAQ: SGHT)
Import activity
33
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
33
Named foreign suppliers
3
Top origins
China · Taiwan
Shared foreign counterparties do not establish that these companies buy from Sight Sciences.
What this tells a buyer
In August 2026, Sight Sciences reported second-quarter 2026 financial results, and in November 2026 it reported third-quarter results and raised its full-year 2026 revenue guidance.
The company's OMNI Surgical System and TearCare System address glaucoma and dry eye disease, and the OMNI Ultra Surgical System received FDA 510(k) clearance in August 2026.
Sight Sciences trades on a public exchange under the ticker SGHT, and in August 2026 it announced Aetna coverage for its OMNI and SION Surgical Systems in the United States.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Sight Sciences is a publicly traded ophthalmic medical device company headquartered in Menlo Park, California, founded in 2011. It employs roughly 100 to 200 people and reports revenue in the range of $77.4 million. The company serves ophthalmologists, optometrists, hospitals, and medical centers in glaucoma and dry eye care. Its own products include the OMNI Surgical System for minimally invasive glaucoma surgery and the TearCare System for heat-based dry eye treatment. In August 2026, it received FDA 510(k) clearance for the OMNI Ultra Surgical System.
At a glance
Attribute | Detail |
|---|---|
Founded | 2011 |
Headquarters | Menlo Park, California |
Employees | 100-200 |
Revenue | 77.4M |
Ownership | Publicly traded (NASDAQ: SGHT) |
What Sight Sciences makes
The company's OMNI Surgical System and TearCare System address glaucoma and dry eye disease, and the OMNI Ultra Surgical System received FDA 510(k) clearance in August 2026.
Trade and customs footprint
In August 2026, Sight Sciences reported second-quarter 2026 financial results, and in November 2026 it reported third-quarter results and raised its full-year 2026 revenue guidance. US customs bill-of-lading records list 33 inbound shipments across 3 foreign suppliers, with top origins including China · Taiwan.
Latest developments
2026-11-04 — Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance | Sight Sciences (sightsciences.com)
2026-08-05 — Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems - United States (sightsciences.com)
2026-08-05 — Sight Sciences Reports Second Quarter 2026 Financial Results | Sight Sciences (sightsciences.com)
2026-08-04 — Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | Sight Sciences (sightsciences.com)
2025-10-17 — Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure | Sight Sciences (sightsciences.com)
2025-09-30 — Sight Sciences, Inc. Amends Loan Agreement With Hercules Capital To Extend Interest-Only Period And Reallocate Tranche | MarketScreener (marketscreener.com)
Company details
Sight Sciences trades on a public exchange under the ticker SGHT, and in August 2026 it announced Aetna coverage for its OMNI and SION Surgical Systems in the United States. Sight Sciences was founded in 2011, has an estimated 100-200 employees, and is headquartered in Menlo Park, California.
Frequently asked questions
What does Sight Sciences do?
Sight Sciences is a publicly traded ophthalmic medical device company headquartered in Menlo Park, California, founded in 2011. It employs roughly 100 to 200 people and reports revenue in the range of $77.4 million. The company serves ophthalmologists, optometrists, hospitals, and medical centers in glaucoma and dry eye care. Its own products include the OMNI Surgical System for minimally invasive glaucoma surgery and the TearCare System for heat-based dry eye treatment. In August 2026, it received FDA 510(k) clearance for the OMNI Ultra Surgical System.
Where is Sight Sciences headquartered?
Sight Sciences is headquartered in Menlo Park, California (4040 Campbell Ave, Menlo Park, California, 94025).
When was Sight Sciences founded?
Sight Sciences was founded in 2011.
How big is Sight Sciences?
Sight Sciences has an estimated 100-200 employees, with revenue in the 77.4M range.
Is Sight Sciences publicly traded?
Publicly traded (NASDAQ: SGHT). Public financial figures are drawn from its filings.
Does Sight Sciences import from overseas suppliers?
US customs bill-of-lading records show 33 inbound shipments for Sight Sciences, with top origins including China · Taiwan.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.